TP53 and acute myeloid leukemia: Follow-up results from ongoing expansion cohorts in AML (NCT03248479) are awaited, and a phase III trial evaluating azacitidine and magrolimab in untreated TP53-mutant AML (NCT04778397) is underway to thoroughly evaluate its therapeutic value to augment remission in TP53-mutant AML.